Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Haleon Ch Sarl currently has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are spread across 3 distinct examiners, meaning that every pending matter is being reviewed by a different individual. The portfolio also spans 3 distinct art units, which indicates a broad distribution of technical subject matter within the biotechnology field. This level of variety suggests that the company's current prosecution efforts are not concentrated in a single niche but are instead subject to the standards of multiple patent office divisions.
The busiest examiner for the portfolio is SHOMER, ISAAC, who is responsible for 1 pending office action. With a total of 3 pending office actions, the workload is distributed such that no single examiner dominates the current prosecution cycle. For practitioners, this means that the success of the portfolio depends on navigating the specific requirements of three different examiners and three different art units. This decentralized structure may lead to varying timelines and outcomes across the different applications, as each examiner and art unit operates under its own specific procedural and technical nuances.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHOMER, ISAAC | 1 | 63.2% | +30.4% |
| BAZARGANI, ARYA AHMADI | 1 | 62.5% | +31.3% |
| DIOP, FATIMATA SAHRA | 1 | 68.6% | +38.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18570337 | NANOEMULSION COMPRISING DICLOFENAC | BAZARGANI, ARYA AHMADI | 14d |
| 17633718 | BI-MATERIAL NOZZLE FOR NASAL WASHES | DIOP, FATIMATA SAHRA | 69d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18570337 | NANOEMULSION COMPRISING DICLOFENAC | BAZARGANI, ARYA AHMADI | 14d |
| 17633718 | BI-MATERIAL NOZZLE FOR NASAL WASHES | DIOP, FATIMATA SAHRA | 69d |
| 18729234 | DICLOFENAC FORMULATIONS | SHOMER, ISAAC | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| 1613 | 1 |
| 3783 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18729234 | DICLOFENAC FORMULATIONS | SHOMER, ISAAC | 1612 | §103 | Final Rejection | — | Pending | Jul 16, 2024 |
| 18570337 | NANOEMULSION COMPRISING DICLOFENAC | BAZARGANI, ARYA AHMADI | 1613 | §103§112 | Final Rejection | 14d | Pending | Dec 14, 2023 |
| 17633718 | BI-MATERIAL NOZZLE FOR NASAL WASHES | DIOP, FATIMATA SAHRA | 3783 | §103§112 | Non-Final OA | 69d | Pending | Feb 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial